Incidence of atrial fibrillation and its effects on long-term follow-up outcomes in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction

Abstract

Objective: The incidence of atrial fibrillation (AF) in patients with ST segment elevation myocardial infarction (STEMI) varies between 7% and 21%, and most of these studies were in the thrombolytic era. However, the frequency of new-onset AF during the primary percutaneous coronary intervention (PCI) period is still unclear. We aimed to investigate the frequency of new-onset AF and its effects on long-term clinical events in patients undergoing primary PCI. Methods: A total of 1,603 patients who were diagnosed with STEMI and underwent primary PCI were included in the study. All the patients were monitored for at least 48 hours after the procedure. The primary endpoint of the study was defined as new-onset AF during hospitalization. Results: The median follow-up period of our study was 44 months. New-onset AF developed in 85 (6.1%) patients. CHADs-VASc > 2, KILLIP > 2, and left atrial diameter were found to be independent predictors for the development of new-onset AF. In the AF (+) group, the all-cause and in-hospital mortality rates were found to be significantly higher. New-onset AF development in patients with STEMI was detected as an independent predictor of in-hospital mortality. Conclusion:In the era of primary percutaneous transluminal coronary angioplasty, new-onset AF rates were found to be lower than the literature data. In addition, new-onset AF was found to be a predictor of in-hospital mortality, and deaths occurred mostly in the early period. Therefore, close follow-up of these patients in the early period and re-evaluation in terms of AF burden when the patient becomes stable are important.

Short Term Prognostic Value of CHA2DS2 -VASc Score in ST Elevation Myocardial Infarction in Patients without Atrial Fibrillation

“…Arslan et al (9) reported that the there was no statistical significant difference between both groups regarding to Killip classification.…”

“…Also, Arslan et al (9) reported that the there was a high Statistical significant difference between both groups regarding CHA2DS2-VASc score (1.6±1 versus 2.7±2 ; P < 0.001). while Li et al (8) found that mean CHA2DS2-VASc scores significantly differed between the AF group and the non-AF group (4.09±1.38 and 3.27±1.51, respectively; P<.001).…”

Incidence and predictors of new‐onset atrial fibrillation in ST‐elevation myocardial infarction: A single‐center study

“… 15 In previous studies, the prevalence of NOAF varied, with reports of 9.3% and 10.1% by Khalfallah and Elsheikh 13 and Aksoy et al, 7 respectively. Arsalan et al 16 reported a prevalence of 6.1%, and Selçuk et al 15 reported 8% among STEMI patients following primary PCI. However, Topaz et al 17 reported AF in 7.4% of cases, with only 2.8% representing NOAF.…”

tPCS as a method for correcting cardiac arrhythmias after percutaneous transluminal coronary angioplasty with stenting in patients with myocardial infarction

“…На начало исследования между исследуемыми группами по сывороточной концентрации β-эндорфина статистически значимых различий не выявлено (p > 0,05). (3,6) 4,4 (3,5) MW-test p = 0,8847 p = 0,3517 p = 0,8794 p = 0,3234 Dunn's test, p 1-2 0,0107 0,0036 0,0303 0,0036 0,1777 0,0061 0,1457 0,9999 5-е сутки 849 (374, 224 5) 86 (48,5) 30 (20,35) 45, 3 (20,35-50) 15,3 (10,65-23,55) 4,4 (4,15-4,7) 4,5 (3,8) MW-test p = 0,0071 p = 0,0043 p = 0,0007 p = 0,9478 Dunn's test, p 2-3 0,0107 0,0036 0,0061 0,0036 0,0018 0,0027 0,9999 0,9999 10-е сутки 180 (113,9-242,2) 77 (59, 21,5 (12,45) 11,8 (6,(15)(16)(17)(18)(19)95) 6,1 (3,7-23, 0,0001 0,0001 0,0001 0,0001 0,0001 0,0001 0,3098 0,9999 В группе 2 на 5-е сутки на фоне применения ТЭС-терапии концентрация β-эндорфина была выше на 38,3%, чем в группе сравнения (p < 0,05). На 10-е сутки в основной группе сывороточная концентрация β-эндорфина была выше на 35,0%, чем в группе сравнения (p < 0,05).…”

“…Чрескожная траслюминальная коронарная ангиопластика (ЧТКА) со стентированием является одним из наиболее перспективных высокотехнологичных методов малоинвазивного хирургического лечения инфаркта миокарда (ИМ) [1]. Наряду с очевидной пользой ЧТКА при лечении ИМ, существуют также определенные риски, к их числу относят нарушения ритма сердца (НРС) [2,3]. Известно, что НРС развиваются в ≈5% случаев после проведения ЧТКА при лечении ИМ и оказывают негативное влияние на исход заболевания [1].…”